Edrecolomab (monoclonal antibody 17-1A), PMID: 9806108
Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma, PMID: 11578913
Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study, PMID: 12241873
Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update, PMID: 29295696
Edrecolomab in the adjuvant treatment of colorectal carcinoma, PMID: 12517501
Edrecolomab in the adjuvant treatment of colorectal carcinoma, PMID: 12517502
Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer, PMID: 11273586
A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma, PMID: 12743982
Technology evaluation: edrecolomab, Centocor Inc, PMID: 11249762
Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study, PMID: 15933423
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581, PMID: 21747085
Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells, PMID: 12176782
The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study, PMID: 15713997
Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow, PMID: 10632331
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies, PMID: 21044305
A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer, PMID: 11182031
Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer, PMID: 19273708
When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab, PMID: 19273695
[Anti-cancer monoclonal antibody], PMID: 15861718
EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs, PMID: 29329202
Marketed therapeutic antibodies compendium, PMID: 22531442
Recent developments in colorectal cancer treatment by monoclonal antibodies, PMID: 17049015
Adjuvant therapy of colon cancer, PMID: 15726511
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment, PMID: 12115595
Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial-to-Mesenchymal Transition, PMID: 29667344
Immunomodulation therapy in colorectal carcinoma, PMID: 10814560
[Adjuvant therapy for colon cancer], PMID: 15497107
EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges, PMID: 17325709
EpCAM: A new therapeutic target for an old cancer antigen, PMID: 14508099
Impact of primary tumor side on the outcomes of patients with non-metastatic colon cancer; a patient-level pooled analysis of two clinical trials, PMID: 29966444
Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer, PMID: 16955700
Lessons learned from the edrecolomab story: how a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy, PMID: 15933417
Monoclonal antibodies in the treatment of colorectal cancer, PMID: 15177487
Monoclonal antibodies as therapeutic agents for cancer, PMID: 15120666
Antibody-targeted immunotherapy for treatment of malignancy, PMID: 11160771
Monoclonal and bispecific antibodies as novel therapeutics, PMID: 16648969
Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside, PMID: 20426706
Adjuvant therapy for colon cancer in the new millenium, PMID: 12705552
Monoclonal antibodies in the treatment of cancer, Part 2, PMID: 12966906
Monoclonal antibodies in the treatment of cancer, Part 1, PMID: 12951753
Edrecolomab (Panorex) as adjuvant therapy for stage II colon cancer, PMID: 12445374
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance), PMID: 27432924
Immunotherapy for colorectal cancer, PMID: 11122811
EpCAM as a target in cancer therapy, PMID: 20385979
Expression of EpCAM in uveal melanoma, PMID: 17125516
[Progress of study on antitumor effects of antibody dependent cell mediated cytotoxicity--review], PMID: 21129296
EpCAM: a potential antimetastatic target for gastric cancer, PMID: 19941073
[Clinical assessment of monoclonal antibodies for the treatment and diagnosis of colorectal cancers], PMID: 11904970
Current concepts in immunotherapy for the treatment of colorectal cancer, PMID: 12018689
Novel immunologic and biologic therapies for breast cancer, PMID: 11122896
Impact of primary tumor side on the outcomes of patients with non-metastatic colon cancer; a patient-level pooled analysis of two clinical trials., PMID:29966444
Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial-to-Mesenchymal Transition., PMID:29667344
EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs., PMID:29329202
Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update., PMID:29295696
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)., PMID:27432924
Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581., PMID:23530100
Marketed therapeutic antibodies compendium., PMID:22531442
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803., PMID:21747089
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581., PMID:21747085
[Progress of study on antitumor effects of antibody dependent cell mediated cytotoxicity--review]., PMID:21129296
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies., PMID:21044305
FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment., PMID:21042730
Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside., PMID:20426706
EpCAM as a target in cancer therapy., PMID:20385979
Letter to the editor: efficacy and safety of anti-Trop antibodies, R. Cubas, M. Li, C. Chen and Q. Yao, Biochim Biophys Acta 1796 (2009) 309-1., PMID:20079406
EpCAM: a potential antimetastatic target for gastric cancer., PMID:19941073
Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer., PMID:19273708
When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab., PMID:19273695
Yeast cell surface display system for determination of humoral response to active immunization with a monoclonal antibody against EpCAM., PMID:18321588
Influence of immunomodulatory drugs on the cytotoxicity induced by monoclonal antibody 17-1A and interleukin-2., PMID:17562330
EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges., PMID:17325709
Expression of EpCAM in uveal melanoma., PMID:17125516
Recent developments in colorectal cancer treatment by monoclonal antibodies., PMID:17049015
Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer., PMID:16955700
Monoclonal and bispecific antibodies as novel therapeutics., PMID:16648969
Expression of epithelial-cell adhesion molecule (Ep-CAM) in small cell lung cancer as defined by monoclonal antibodies 17-1A and BerEP4., PMID:16227163
Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study., PMID:15933423
Lessons learned from the edrecolomab story: how a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy., PMID:15933417
[Anti-cancer monoclonal antibody]., PMID:15861718
Adjuvant therapy of colon cancer., PMID:15726511
The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study., PMID:15713997
[Adjuvant therapy for colon cancer]., PMID:15497107
Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma., PMID:15289873
Monoclonal antibodies in the treatment of colorectal cancer., PMID:15177487
Monoclonal antibodies as therapeutic agents for cancer., PMID:15120666
Prevention of peritoneal carcinomatosis from human gastric cancer cells by adjuvant-type intraperitoneal immunotherapy in a SCID mouse model., PMID:14593230
EpCAM: A new therapeutic target for an old cancer antigen., PMID:14508099
Monoclonal antibodies in the treatment of cancer, Part 2., PMID:12966906
Immune changes in patients with colorectal cancer treated by adjuvant therapy with monoclonal antibody 17-1A: a pilot study., PMID:12962368
Monoclonal antibodies in the treatment of cancer, Part 1., PMID:12951753
A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma., PMID:12743982
Adjuvant therapy for colon cancer in the new millenium., PMID:12705552
Edrecolomab in the adjuvant treatment of colorectal carcinoma., PMID:12517502
Edrecolomab in the adjuvant treatment of colorectal carcinoma., PMID:12517501
Highlights from: 38th annual meeting of the American Society of Clinical Oncology., PMID:12453319
Edrecolomab (Panorex) as adjuvant therapy for stage II colon cancer., PMID:12445374
25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000., PMID:12445373
Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study., PMID:12241873
Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells., PMID:12176782
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment., PMID:12115595
For research use only. Not for human or drug use.
